Coagulation Mechanisms Dr. Nervana Bayoumy

Similar documents
Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

Sign up to receive ATOTW weekly -

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Physiology Unit 3 HEMATOLOGY

Basic coagulation applications and case studies

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Coagulation in perspective: Blood management. Objectives

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

*NCCT is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program, provider #122.

Ch 13: Blood. What does blood do? Transport: Regulation: Protection:

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~

Chapter 19b Blood, cont d

Overview of Anatomy and Physioloy II Second Year Students

Methods of Biomaterials Testing. Special Biology: Blood & Vessel

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Dr. Suzana Voiculescu

Rheological Properties of Fibrin Clots

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

COAGULATION: BASIC PRINCIPLES. Peyman Eshghi Prof. of Pediatric Hematology & Oncology

Hematology Emergencies: Problems with Platelets

OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY

The Coagulation Workup In The Office Setting

proteins. The ECs are supported by a collagen-rich

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Category Storage Shelf Life Additional Criteria

Table of Contents. Introduction. Worldwide Market and Technology Overview

Why measure thrombin generation? How does measurement of thrombin generation work? Sample material / pre-analytics Test performance Applications

2 Thomas G. DeLoughery

EDUCATIONAL COMMENTARY D-DIMER UPDATE

Evaluation of Unexplained Prolonged APTT &/or PT Review & Update

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,

Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1

Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม

SAMPLE H21-A5. January 2008

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

SEED Coagulation. Sysmex Educational Enhancement and Development April 2014

Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase

Marcia L. Zucker, Ph.D. ZIVD LLC

Serine Proteases and their Inhibitors

A MANUFACTURING PROCESS TO OBTAIN A HIGHLY-PURIFIED TRIPLE-SECURED FIBRINOGEN PRODUCT

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017

ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS

Evaluation of the Bleeding Patient

Molecular BioSystems PAPER

Anticlotting mechanisms 1: physiology and pathology

Regulation of the protein C anticoagulant pathway by C4b-binding protein. Robbert van de Poel

Marcia L. Zucker, Ph.D. ZIVD LLC

Dr Kate Talks, Consultant Haematologist, Newcastle upon Tyne Hospitals NHS Trust Nov 2012

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Involves interaction of 4 systems Vascular system Platelet system* Clotting proteins* Fibrinolytic system

Common Inherited Bleeding Disorders

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?

Managing the Bleeding Patiient

Suitability of analytical methods for detection of thrombogenic factor XIa in Privigen

Product Data Sheet - TRUEMAB

FACTOR XIII DEFICIENCY IN PAKISTAN

Human Plasmin Activity Assay ELISA Kit

Blood is 55% Plasma (Liquid)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

CHANGE IN PLATELET USAGE

Surgical Adhesives in Facial Plastic Surgery

UMass Memorial Medical Center Worcester, MA

ROTEM Basic Interpretation Guide

A Novel Method for the Quantitative Evaluation of Fibrinogen Coagulation

2015 Catalogue Coagulation

Success in surgical procedures in veterinary patients depends on proper surgical

EFFICACY OF NANOPARTICLES IN ACHIEVING HEMOSTASIS. A Thesis Presented to. The Faculty of the Graduate School. At the University of Missouri

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors

Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.

Bleeding Emergencies. Gregory W. Hendey, MD, FACEP Professor of Clinical Emergency Medicine UCSF Fresno

If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS)

R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal,

Heparin: Powerful and Instantaneously acting Anticoagulant

Autologous Fibrinogen Purification and Concentration For Use in Fibrin Sealant

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS

Critical Quality Attributes for Blood Products. Tim Lee, Ph.D. OBRR/CBER/FDA 12 January 2009 WCBP

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Current laboratory practices in the diagnosis and management of haemophilia

AssayMax Human Factor XI ELISA Kit

Effect of Fibrinogen and Ca2+ on the Thrombin-Catalyzed Proteolytic Event That Triggers Activation of Factor XI11

Biological evaluation of medical devices. Part 4: Selection of tests for interactions with blood

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

Guideline on core SmPC for human fibrinogen products

Clotting tests. June 2009 V Diagnostica Stago - All right reserved

Customer Service. For further product information, technical advice, prices or to place an order contact. Phone:

Transcription:

Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology

Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand the role of calcium ions during clotting cascades. 3. Describe the cascades of intrinsic and extrinsic pathways for clotting. 4. Recognize process of fibrinolysis and function of plasmin 5. Recognize some conditions causing excessive bleeding 6. Understand some important anticoagulants and their mechanism of action

Mechanism of Blood Coagulation A crucial physiological balance exists between factors promoting coagulation (procoagulants) and factors inhibiting coagulation (anticoagulants). Coagulation of blood depends on the balance between these two factors. Disturbances in this balance could lead to thrombosis or bleeding

Hemostasis: prevention or stoppage of blood loss. Hemostatic Mechanisms: 1. Vessel wall (Vasoconstriction) 2. Platelets (Production and activation, Platelets Plug formation) 3. Blood coagulation Clot formation (intrinsic & extrinsic pathways) 4. Fibrinolysis

Coagulation: Formation of fibrin meshwork (Threads) to form a CLOT

Clotting Factors Factors I II III IV V VII VIII IX X XI XII XIII Names Fibrinogen Prothrombin Thromboplastin (tissue factor) Calcium Labile factor Stable factor Antihemophilic factor Antihemophilic factor B Stuart-Prower factor Plasma thromboplastin antecedent (PTA) Hageman factor Fibrin stablizing factors

Prothrombin (factor II): - is a plasma protein, α2-globulin - present in normal plasma in a concentration of 15 mg/dl - it is unstable protein that can be split easily into thrombin - it is continually formed by the liver Vitamin K is important for normal production of prothrombin by the liver. Lack of vit K or liver disease can decrease the of prothrombin formation to a very low level >>>> bleeding Thrombin: - is a protein enzyme with weak proteolytic capabilities - it acts on fibrinogen to form one molecule of fibrin monomer - fibrin monomers polymerize with one another to form fibrin fibers - it activates factor XIII

Fibrin-stabilizing factor (XIII): - is a plasma protein - it is also released from platelets that is entrapped in the clot - it must be activated before it affects the fibrin fibers - activated XIII factor operates as an enzyme causing additional strength of fibrin meshwork Fibrinogen (factor I): - is a high-molecular-weight plasma protein - it is continually formed by the liver - little or no fibrinogen leak from blood vessels Blood Clot: - is composed of a meshwork of fibrin fibers running in all directions and entrapping blood cells, platelets, plasma.

Intrinsic system HMWK Kallik. Pre-K XII XIIa XI HMWK XIa Extrinsic system tissue factor VIIa Ca ++ VII IX Ca ++ IXa X Xa X Final common pathway Prothrombin II Fibrinogen I Ca ++, PL, VIII Ca ++, PL, V thrombin IIa Fibrin monomer XIIIa Ca ++ XIII Fibrin

Initiation Cell based model Fibroblast TF VIIa IXa Xa Prothrombin Propagation Thrombin Thrombin VIIIa XIa Prothrombin Xa IXa XIa Platelet Amplification Activated platelets

Thrombin Thrombin changes fibrinogen to fibrin Thrombin is essential in platelet morphological changes to form primary plug Thrombin stimulates platelets to release ADP & thromboxane A2; both stimulate further platelets aggregation Activates factor V 12

ACTION OF THROMBIN ON FIBRONOGEN TO FORM FIBRIN

Blood coagulation (clot formation) A series of biochemical reactions leading to the formation of a blood clot within few seconds after injury Prothrombin (inactive thrombin) is activated by a long intrinsic or short extrinsic pathways This reaction leads to the activation of thrombin enzyme from inactive form prothrombin Thrombin will change fibrinogen (plasma protein) into fibrin (insoluble protein) 14

Intrinsic pathway The trigger is the activation of factor XII by contact with foreign surface, injured blood vessel, and glass. Activated factor XII will activate factor XI Activated factor Xl will activate IX Activated factor IX + factor VIII + platelet phospholipid factor (PF3)+ Ca activate factor X Following this step the pathway is common for both intrinsic and extrinsic 15

Extrinsic pathway Triggered by material released from damaged tissues (tissue thromboplastin) Tissue thromboplastin + VII + Ca activate X Common pathway Activated factor X + factor V +PF3 + Ca activate prothrombin activator; a proteolytic enzyme which activates prothrombin. Activated prothrombin activates thrombin Thrombin acts on fibrinogen and change it into insoluble thread like fibrin. Factor XIII + Calcium strong fibrin (strong clot) 16

Activation of Blood Coagulation Intrinsic Pathway: all clotting factors present in the blood Extrinsic Pathway: triggered by tissue factor (thromboplastin) Common Pathway

Fibrinolysis Formed blood clot can either become fibrous or dissolved. Fibrinolysis (dissolving) = Break down of fibrin by naturally occurring enzyme plasmin therefore prevent intravascular blocking. There is a balance between clotting and fibrinolysis Excess clotting blocking of Blood Vessels Excess fibrinolysis tendency for bleeding 18

Fibrinolysis Tissue Plasminogen Activator (t-pa) Released from injured tissues and vascular endothelium Plasminogen (Protein in the blood) Plasmin Anti-activators Fibrinogen Fibrin Thrombin FDP* FDP*: Fibrin Degradation Products

Plasmin Is present in the blood in an inactive form plasminogen Is activated by tissue plasminogen activators (t-pa) in blood. Digests intra & extra vascular deposit of Fibrin fibrin degradation products (FDP) Unwanted effect of plasmin is the digestion of clotting factors 20

Plasmin Plasmin is controlled by: Tissue Plasminogen Activator Inhibitor (TPAI) Antiplasmin from the liver Uses: Tissue Plasminogen Activator (TPA) used to activate plasminogen to dissolve coronary clots 21

Prevention of blood clotting in the normal vascular system and Anticoagulants Endothelial surface factors - Smoothness of the ECS. - Glycocalyx layer - Thrombomodulin protein Fibrin fibers, adsorbs ~ 90% of thrombin to removes it from circulating blood Antithrombin III, combines the remaining thrombin and removes it from blood Heparin, combines with Antithrombin III and quickly removes thrombin from blood - Liver, lungs, mast cells, basophils

Conditions that cause excessive bleeding Vitamin K Deficiency - Prothrombin, Factor VII, Factor IX, Factor X require vitamin K for their synthesis - Hepatitis, Cirrhosis, acute yellow atrophy AND GI disease Hemophilia bleeding tendency. X-linked disease. Affects males. 85% due to Factor VIII deficiency (hemophilia A), and 15% due to Factor IX deficiency (hemophilia B). Thrombocytopenia Very low number of platelets in blood (< 50,000/μl) Thrombocytopenia purpura, hemorrhages throughout all the body tissues Idiopathic Thrombocytopenia, unknown cause.